Painreform Ltd  (PRFX)
Other Ticker:  

Painreform Ltd

Business Description

Painreform Ltd is a pharmaceutical company that specializes in the development and commercialization of innovative and effective pain management therapies. The company is headquartered in Israel and operates globally, aiming to provide solutions for various types of acute and chronic pain.

Painreform*s primary focus is on developing novel drug formulations using its proprietary technology platform, which combines known analgesic drugs with its innovative delivery system. This approach allows for enhanced drug efficacy, increased duration of action, and improved patient compliance compared to conventional pain medications.

The company*s core product is PRF-110, a liposomal formulation of ropivacaine (a local anesthetic) that is designed to provide effective and long-lasting pain relief for post-operative and acute pain. The liposomal encapsulation enables a controlled and sustained release of the drug, resulting in prolonged pain relief and reduced side effects. PRF-110 has the potential to revolutionize post-operative pain management and improve patients* quality of life.

Painreform*s development pipeline also includes PRF-210, a novel liposomal formulation of ketorolac (a nonsteroidal anti-inflammatory drug) for the treatment of acute and chronic pain. This formulation is being investigated for its potential to provide superior pain relief, longer duration of action, and reduced systemic exposure compared to currently available pain medications.

The company is committed to conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. Painreform collaborates with leading academic institutions and clinical centers to ensure the highest scientific standards and regulatory compliance.

Painreform also holds a robust intellectual property portfolio, including numerous granted and pending patents. This intellectual property protection provides a competitive advantage and ensures exclusivity for its innovative drug formulations and delivery systems.

In addition to its research and development efforts, Painreform is also focused on establishing strategic partnerships and collaborations with pharmaceutical companies and healthcare organizations to accelerate the commercialization and global distribution of its products.

Overall, Painreform Ltd is at the forefront of developing cutting-edge pain management solutions that have the potential to revolutionize the way pain is treated and managed. With its innovative drug formulations, proprietary delivery technology, and commitment to scientific excellence, the company aims to improve patients* lives and meet the growing need for effective pain management therapies.

View Company Supplier View Company Competition View Company Customers


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com